
Piptabrex 4.5 Injection
Marketer
Mcbrex Lifesciences
Salt Composition
Piperacillin (4000mg) + Tazobactum (500mg)
Overview Piptabrex 4.5 Injection
Combiflox 4.5 Injection, a dual-antibiotic formulation, combats diverse bacterial infections by eliminating microorganisms. Administered solely by healthcare providers, its dosage and frequency are determined by your physician based on infection severity. Strict adherence to prescribed usage is crucial. Potential side effects include gastrointestinal upset (nausea, vomiting, diarrhea), skin rashes, and localized injection site reactions (pain, swelling, redness). Persistent or worsening symptoms necessitate medical consultation. Prior to treatment, disclose any antibiotic allergies, kidney, or liver conditions; adjustments to dosage or alternative medications may be necessary. Under medical guidance, this injection is generally deemed safe for pregnant and breastfeeding individuals.
Uses of Piptabrex 4.5 Injection
Infections caused by bacteria
Major Benefits of Piptabrex 4.5 Injection:
The medication will be administered by your physician or their nursing staff; self-medication is strongly discouraged.
Common Side effects of Piptabrex 4.5 Injection:
- Nausea
- Vomiting
- Diarrhea
- Rash
- Allergic reaction
How to use Piptabrex 4.5 Injection:
This medication will be administered by your physician or their designated nursing staff; self-medication is strictly prohibited.
How Piptabrex 4.5 Injection works:
Piptabrex 4.5 Injection merges Piperacillin, an antibiotic, with Tazobactum, a beta-lactamase inhibitor. Piperacillin's mechanism involves disrupting bacterial cell wall synthesis, crucial for bacterial viability. Tazobactum's role is to counteract bacterial resistance mechanisms, thereby bolstering Piperacillin's antibacterial effect.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Piptabrex 4.5 Injection and alcohol consumption.
PregnancySAFE IF PRESCRIBED
The use of Piptabrex 4.5 Injection during pregnancy is typically regarded as safe. Preclinical trials in animals have revealed minimal or no negative consequences for fetal development; however, data from human studies are scarce.
Breast feedingSAFE IF PRESCRIBED
The injectable formulation of Piptabrex, 4.5 mg/mL, poses no known breastfeeding risk. Research in humans indicates minimal to negligible transfer of the medication into breast milk, resulting in no identified harm to the infant.
DrivingCONSULT YOUR DOCTOR
Driving ability may be affected by Piptabrex 4.5 Injection; however, the extent of this effect is unknown. Refrain from driving if experiencing symptoms impairing concentration or reaction time.
KidneyCAUTION
For individuals with kidney impairment, administering Piptabrex 4.5 Injection requires careful consideration. Dosage modification of Piptabrex 4.5 Injection might be necessary. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Piptabrex 4.5 Injection in individuals with hepatic impairment appears to pose minimal risk. Current evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
What if you forget to take Piptabrex 4.5 Injection :
Omit a Piptabrex 4.5 Injection dose? Seek your physician's advice.
Facts to Know About Piptabrex 4.5 Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
